Smith & Nephew plc vs Vanguard S&P 500 ETF — how do they compare? Smith & Nephew plc trades at $30.23 (market cap $12.54B), while Vanguard S&P 500 ETF trades at $710.13. The key difference: Smith & Nephew plc pays a 2.65% dividend while Vanguard S&P 500 ETF pays none, and Vanguard S&P 500 ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| SNN | VOO | |
|---|---|---|
Market Cap | $12.54B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $38.70 | $710.71 |
52-Week Low | $28.73 | $580.93 |
Enterprise Value | $15.57B | — |
Dividend Yield | 2.65% | — |
Signals from Pluang's Aura AI — not financial advice
SNN trades at $29.87, down 0.71% on the day, with a bearish technical signal. The company reported Q2 2026 revenue growth of 1.6%, below expectations, leading to a reduced full-year outlook. Fundamentals show improvement with 2025 revenue of $6.16B and net income of $625M, yielding a 10.08% margin, though recent earnings have been mixed. The balance sheet remains solid with $619M in cash and a debt-to-asset ratio of 29.75% for 2025.
The outlook is cautious due to near-term operational weakness, particularly in U.S. Orthopaedics, offset by innovation in robotics and wound care. Risks include execution challenges and competitive pressures, while analyst sentiment is predominantly Hold. The stock's valuation appears reasonable with a P/E of 20.41, but growth catalysts are needed for significant upside.
VOO trades at $710.12, down slightly by 0.07% amid mixed market signals. Technical indicators show a bullish trend with strong moving average support, though oscillators suggest caution with RSI levels indicating overbought conditions. The ETF remains a core holding for broad US market exposure, with institutional interest demonstrated by recent position increases from advisory firms.
The outlook for VOO remains positive given its low-cost S&P 500 exposure, though current market valuations present near-term risk. Key catalysts include corporate earnings growth and inflation data, while risks center on market breadth concerns and potential profit-taking at record highs.
Trailing returns across standard periods
Latest headlines on both assets
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →